Trial · NCT01916941
Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin
NCT01916941, Not applicable, Completed, University of New Mexico; results first posted 2017-10-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin. Trials, record NCT01916941. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01916941
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin
- NCT number
- NCT01916941
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 36 participants, actual
- Lead sponsor
- University of New Mexico
- Conditions
- Alcohol Use Disorder
- Interventions
- Prazosin, Placebo
- First posted
- 2013-08-06
- Last updated
- 2017-10-17
- Results first posted
- 2017-10-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) | from 2-4 weeks and from 4-6 weeks |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) | from 2-4 weeks and from 4-6 weeks | drinks per week | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) | Prazosin | from 2-4 weeks | 13.65 | Standard Deviation 18.92 | drinks per week |
| Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) | Placebo | from 2-4 weeks | 14.55 | Standard Deviation 17.29 | drinks per week |
| Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) | Prazosin | from 4-6 weeks | 15.11 | Standard Deviation 23.66 | drinks per week |
| Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) | Placebo | from 4-6 weeks | 11.11 | Standard Deviation 15.01 | drinks per week |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prazosin | 18 | |
| Overall Study | STARTED | Placebo | 18 | |
| Overall Study | COMPLETED | Prazosin | 13 | |
| Overall Study | COMPLETED | Placebo | 14 | |
| Overall Study | NOT COMPLETED | Prazosin | 5 | |
| Overall Study | NOT COMPLETED | Placebo | 4 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness on standing | Cardiac disorders | Prazosin | 10 | 18 | |
| other | Dizziness on standing | Cardiac disorders | Placebo | 4 | 18 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prazosin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Prazosin | 10 | 18 |
| Total, other adverse events | Placebo | 4 | 18 |
| Total, serious adverse events | Prazosin | 0 | 18 |
| Total, serious adverse events | Placebo | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23AA021156 | Neural Mechanisms of Change During Alcohol Use DisorderTreatment with Prazosin | WILCOX, CLAIRE | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2013 to 2017 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Prazosin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01916941
GET https://conductscience.org/api/trials/v1/NCT01916941/registered